Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...

Everest Medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...

These results are significant for mRNA vaccine research and ... Today, many other lipid nanoparticle-oligonucleotide formulations have been developed and are under clinical evaluation for the ...

Scientists unlock the potential of fenugreek-based lipid nanoparticles to improve diabetes ... validation through in vivo studies and clinical trials is required. The research mapped interactions ...

Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics ... technology platforms, research and clinical development plans, and preclinical data and other statements ...

PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics ... technology platforms, research and clinical development plans, and preclinical data and other statements ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...